GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine

J Neuropsychiatry Clin Neurosci. 2015;27(2):162-4. doi: 10.1176/appi.neuropsych.13120389.

Abstract

Association between gastric inhibitory polypeptide receptor polymorphism, rs10423928, and body mass index in olanzapine-treated schizophrenia was examined. Body mass index change for the A/T+A/A genotypes was significantly higher than that for the T/T genotype. rs10423928 may predict weight gain in schizophrenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines / therapeutic use*
  • Body Mass Index
  • Body Weight / drug effects
  • Body Weight / genetics*
  • Female
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Olanzapine
  • Pharmacogenetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Receptors, Gastrointestinal Hormone / genetics*
  • Schizophrenia* / drug therapy
  • Schizophrenia* / genetics
  • Schizophrenia* / physiopathology
  • Young Adult

Substances

  • Antipsychotic Agents
  • Receptors, Gastrointestinal Hormone
  • Benzodiazepines
  • gastric inhibitory polypeptide receptor
  • Olanzapine